|
| related topics |
| {product, candidate, development} |
| {provision, law, control} |
| {stock, price, share} |
| {personnel, key, retain} |
| {product, liability, claim} |
| {stock, price, operating} |
| {property, intellectual, protect} |
| {control, financial, internal} |
| {cost, regulation, environmental} |
| {competitive, industry, competition} |
| {regulation, government, change} |
|
|
Our products are in an early stage of research and development and may not be determined to be safe or effective.
We have incurred net losses since our inception and we may not achieve or sustain profitability.
If we fail to attract significant additional capital, we may be unable to continue to successfully develop our products.
If we fail to receive necessary regulatory approvals, we will be unable to commercialize our products.
We may fail to compete effectively, particularly against larger, more established pharmaceutical companies, causing our business to suffer.
If we lose key personnel or are unable to attract and retain additional, highly skilled personnel required for our activities, our business will suffer.
Asserting, defending and maintaining our intellectual property rights could be difficult and costly, and our failure to do so will harm our ability to compete and the results of our operations.
If our strategic relationships are unsuccessful, our business could be harmed.
We may be subject to product liability lawsuits and our insurance may not be adequate to cover damages.
Continuing efforts of government and third party payers to contain or reduce the costs of health care may adversely affect our revenues and future profitability.
If we fail to establish strategic relationships with larger pharmaceutical partners, our business may suffer.
We use hazardous substances in our research activities
Our right to issue preferred stock, our classified Board of Directors and Oregon Anti-Takeover
laws may delay a takeover attempt and prevent or frustrate any attempt to replace or remove the then current management of the Company by shareholders.
Our stock price is volatile and may fluctuate due to factors beyond our control.
The significant number of our shares of Common Stock eligible for future sale may cause the price of our common stock to fall.
We do not expect to pay dividends in the foreseeable future.
Full 10-K form ▸
|
|
| related documents |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 1010086--3/13/2008--SIGA_TECHNOLOGIES_INC |
| 908259--3/14/2008--OXIGENE_INC |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 1017491--3/12/2008--NEXMED_INC |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 1020214--2/27/2006--CERUS_CORP |
| 874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA |
| 708717--10/15/2007--ALFACELL_CORP |
| 897075--3/14/2007--REPROS_THERAPEUTICS_INC. |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 908259--3/14/2007--OXIGENE_INC |
| 1038133--3/30/2007--HESKA_CORP |
| 1038133--3/31/2006--HESKA_CORP |
| 817785--4/4/2007--IMMUNE_RESPONSE_CORP |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 1017491--3/26/2007--NEXMED_INC |
| 1038133--3/16/2009--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
| 1038133--2/22/2010--HESKA_CORP |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 12239--4/4/2008--SPHERIX_INC |
| 907562--3/3/2006--DYAX_CORP |
| 1028358--3/31/2008--GENITOPE_CORP |
| 810509--3/31/2008--NEOPROBE_CORP |
| 1096560--3/12/2008--SULPHCO_INC |
| 1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 71478--3/28/2008--LIPID_SCIENCES_INC/ |
| 1020214--3/11/2010--CERUS_CORP |
|